此次公司获得复方聚乙二醇电解质散(Ⅲ)注册证书，标志着公司具备了在国内市场销售该规格药品的资 格，将进一步丰富公司产品管线和产品品类，增强了公司的核心竞争力。 一品红（300723）(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司于近日收到国家药 品监督管理局核准签发的关于复方聚乙二醇电解质散(Ⅲ)的《药品注册证书》，复方聚乙二醇电解质散 (Ⅲ)适应症为：用于以下情况之前的患者结肠清洁准备：--内窥镜或放射检查--结肠手术，本品适用于成 人。 ...

Core Viewpoint - The company Yipinhong (300723.SZ) has received the drug registration certificate for Compound Polyethylene Glycol Electrolyte Powder (III) from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its product pipeline and core competitiveness [1] Group 1 - The registration certificate is specifically for the use of the product in bowel cleansing preparation for patients prior to procedures such as endoscopy, radiological examinations, and colorectal surgery, applicable to adults [1] - This approval signifies the company's capability to market this specific drug formulation in China, thereby expanding its product offerings [1] - The introduction of this product is expected to strengthen the company's competitive edge in the pharmaceutical industry [1]